AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 30885800 — intervention group
Group type: COMPARATOR
Intervention: TBI education alone
Number of subjects: 0
Study 29895001 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-Behavioral Therapy (CBT)
Number of subjects: 107
Study 29895001 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychodynamic Therapy (PDT)
Number of subjects: 107
Study 29895001 — intervention group
Group type: COMPARATOR
Intervention: Waiting List (WL)
Number of subjects: 107
Study 25662284 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin therapy
Number of subjects: 51
Study 25662284 — intervention group
Group type: COMPARATOR
Intervention: No statin therapy (Control)
Number of subjects: 51
Study 24785989 — intervention group
Group type: EXPERIMENTAL
Intervention: Solifenacin 5 mg, 6 hours before surgery and 5 mg per day after surgery for 2 weeks
Number of subjects: 116
Study 24785989 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 116
Study 22801019 — intervention group
Group type: EXPERIMENTAL
Intervention: CIC‐HFA 74 μg
Number of subjects: 1111
Study 22801019 — intervention group
Group type: EXPERIMENTAL
Intervention: CIC‐HFA 148 μg
Number of subjects: 1111
Study 22801019 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1111
Study 19647859 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 applications of 3 ml 2% cidofovir in Intrasite gel in a cervical cap
Number of subjects: 53
Study 19647859 — intervention group
Group type: COMPARATOR
Intervention: Placebo (the same volume of Intrasite alone)
Number of subjects: 53
Study 17889767 — intervention group
Group type: EXPERIMENTAL
Intervention: CustomVue laser
Number of subjects: 39
Study 17889767 — intervention group
Group type: COMPARATOR
Intervention: CustomCornea laser
Number of subjects: 39
Study 15238279 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg copper/L
Number of subjects: 1365
Study 15238279 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg copper/L
Number of subjects: 1365
Study 15238279 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 mg copper/L
Number of subjects: 1365
Study 15238279 — intervention group
Group type: EXPERIMENTAL
Intervention: > 6 mg copper/L
Number of subjects: 1365
Study 15238279 — intervention group
Group type: COMPARATOR
Intervention: < 0.01 mg copper/L (control)
Number of subjects: 1365
Study 11434226 — intervention group
Group type: EXPERIMENTAL
Intervention: Thought suppression
Number of subjects: 0
Study 11434226 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical participants
Number of subjects: 0
Study 7706702 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 min exercise on a stationary bicycle for 4 days
Number of subjects: 17
Study 7706702 — intervention group
Group type: COMPARATOR
Intervention: 10 min exercise on a stationary bicycle for 4 days
Number of subjects: 17
Study 2689970 — intervention group
Group type: EXPERIMENTAL
Intervention: Ventilatory muscle endurance training (breathing through an inspiratory resistor equivalent to 85% SIP for 15 minutes twice daily, 5 days a week for 8 weeks)
Number of subjects: 12
Study 2689970 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 12
Study 2689970 — intervention group
Group type: COMPARATOR
Intervention: Both groups (pooled data)
Number of subjects: 12
Study 2689970 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 12
Study 2689970 — intervention group
Group type: EXPERIMENTAL
Intervention: Training group
Number of subjects: 12
Study 4557583 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (administered in 4 divided doses beginning 24 hours before and ending 2 hours prior to smoking)
Number of subjects: 0
Study 4557583 — intervention group
Group type: COMPARATOR
Intervention: Placebo (administered in 4 divided doses beginning 24 hours before and ending 2 hours prior to smoking)
Number of subjects: 0
Study 31405532 — intervention group
Group type: EXPERIMENTAL
Intervention: Stretching regimen (three daily exercises to stretch the calves and hamstrings)
Number of subjects: 15
Study 31455286 — intervention group
Group type: EXPERIMENTAL
Intervention: Cesarean hysterectomy (Group A, n=38)
Number of subjects: 102
Study 31455286 — intervention group
Group type: EXPERIMENTAL
Intervention: Cesarean section with cervical inversion and ligation of both uterine arteries (Group B, n=48)
Number of subjects: 102
Study 31455286 — intervention group
Group type: EXPERIMENTAL
Intervention: Placenta left in place (Group C, n=16)
Number of subjects: 102
Study 27461209 — intervention group
Group type: EXPERIMENTAL
Intervention: CT cohort (40 patients)
Number of subjects: 80
Study 27461209 — intervention group
Group type: COMPARATOR
Intervention: Angiography cohort (40 patients)
Number of subjects: 80
Study 27461209 — intervention group
Group type: EXPERIMENTAL
Intervention: Both cohorts
Number of subjects: 80
Study 25820848 — intervention group
Group type: EXPERIMENTAL
Intervention: Pilates exercises (5 times a week, 30 min per session for 8 weeks)
Number of subjects: 80
Study 23550251 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured home blood pressure monitoring education program
Number of subjects: 240
Study 23550251 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 240
Study 21418455 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin detemir (IDet)
Number of subjects: 82
Study 21418455 — intervention group
Group type: COMPARATOR
Intervention: NPH insulin
Number of subjects: 82
Study 19928397 — intervention group
Group type: EXPERIMENTAL
Intervention: FLC method
Number of subjects: 40
Study 19928397 — intervention group
Group type: COMPARATOR
Intervention: FFT method
Number of subjects: 40
Study 19928397 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated threshold search protocol using the FLC method
Number of subjects: 40
Study 19928397 — intervention group
Group type: EXPERIMENTAL
Intervention: Simultaneous recording of ASSR for both the FFT and FLC method
Number of subjects: 40
Study 16700202 — intervention group
Group type: COMPARATOR
Intervention: Oral analgesia (metamizol and oral morphine)
Number of subjects: 200
Study 16700202 — intervention group
Group type: EXPERIMENTAL
Intervention: Periprosthetic nerve blockade with 2% mepivacaine
Number of subjects: 200
Study 15214597 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate physical activity (PA) combined with weight loss and a balanced diet
Number of subjects: 0
Study 15214597 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking
Number of subjects: 0
Study 15214597 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity (PA)
Number of subjects: 0
Study 10958216 — intervention group
Group type: EXPERIMENTAL
Intervention: Rabeprazole 10 mg
Number of subjects: 288
Study 10958216 — intervention group
Group type: EXPERIMENTAL
Intervention: Rabeprazole 20 mg
Number of subjects: 288
Study 10958216 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 288
Study 9476695 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (0, 50, or 100 mg per hour for 5 hours, total of 0, 250, or 500 mg)
Number of subjects: 22
Study 7885978 — intervention group
Group type: EXPERIMENTAL
Intervention: Ampicillin-sulbactam 3 g
Number of subjects: 136
Study 7885978 — intervention group
Group type: COMPARATOR
Intervention: Cefoxitin 2 g
Number of subjects: 136
Study 2826611 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous acyclovir
Number of subjects: 50
Study 2826611 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 31789585 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyberbullying perpetration
Number of subjects: 1390
Study 31789585 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness
Number of subjects: 1390
Study 31789585 — intervention group
Group type: EXPERIMENTAL
Intervention: Depression
Number of subjects: 1390
Study 29511994 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral branched-chain amino acids (BCAAs) for 28 days
Number of subjects: 18
Study 29511994 — intervention group
Group type: COMPARATOR
Intervention: No supplementation (control)
Number of subjects: 18
Study 26682691 — intervention group
Group type: EXPERIMENTAL
Intervention: Anserine/Carnosine Supplementation (ACS) 1.0 g daily for 3 months
Number of subjects: 39
Study 26462765 — intervention group
Group type: EXPERIMENTAL
Intervention: Mucinex® 1200 mg (2 × 600 mg extended release tablets)
Number of subjects: 38
Study 26462765 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study 23396496 — intervention group
Group type: EXPERIMENTAL
Intervention: LCω‐3PUFA (fish oil)
Number of subjects: 39
Study 23396496 — intervention group
Group type: COMPARATOR
Intervention: Placebo (monounsaturated oil)
Number of subjects: 39
Study 21468659 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer Mentor condition
Number of subjects: 169
Study 18378377 — intervention group
Group type: EXPERIMENTAL
Intervention: 38% silver diamine fluoride every 12 months
Number of subjects: 10
Study 18378377 — intervention group
Group type: COMPARATOR
Intervention: 5% sodium fluoride varnish every 3 months
Number of subjects: 10
Study 16929626 — intervention group
Group type: EXPERIMENTAL
Intervention: Deaf individuals (bilingual, nasal-breathing, bilingual, buccal-breathing, oralist, nasal-breathing)
Number of subjects: 50
Study 16929626 — intervention group
Group type: COMPARATOR
Intervention: Healthy volunteers (control group)
Number of subjects: 50
Study 12716270 — intervention group
Group type: EXPERIMENTAL
Intervention: Divalproex sodium
Number of subjects: 120
Study 12716270 — intervention group
Group type: COMPARATOR
Intervention: Olanzapine
Number of subjects: 120
Study 11153591 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 g alcohol x kg body weight consumed 90 min prior to sleep time
Number of subjects: 21
Study 11153591 — intervention group
Group type: COMPARATOR
Intervention: Non-alcohol night (control)
Number of subjects: 21
Study 9101212 — intervention group
Group type: EXPERIMENTAL
Intervention: Nilutamide 300 mg/day for 1 month and 150 mg thereafter
Number of subjects: 868
Study 9101212 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 868
Study 7968873 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Number of subjects: 0
Study 2442552 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisinopril (20-80 mg/day)
Number of subjects: 136
Study 2442552 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine (40-80 mg/day)
Number of subjects: 136
Study 31600823 — intervention group
Group type: EXPERIMENTAL
Intervention: Potentially misclassified intrapartum stillbirths (180 out of 391 recorded intrapartum stillbirths) with FHS at admission and no resuscitation initiated after birth.
Number of subjects: 39562
Study 31600823 — intervention group
Group type: EXPERIMENTAL
Intervention: Potentially misclassified intrapartum stillbirths (180) with FHS present 15 minutes before birth.
Number of subjects: 39562
Study 31600823 — intervention group
Group type: EXPERIMENTAL
Intervention: Potentially misclassified intrapartum stillbirths (180) with complications during labor.
Number of subjects: 39562
Study 31600823 — intervention group
Group type: EXPERIMENTAL
Intervention: Potentially misclassified intrapartum stillbirths (180) with birthweight less than 2500 g.
Number of subjects: 39562
Study 31600823 — intervention group
Group type: EXPERIMENTAL
Intervention: Potentially misclassified intrapartum stillbirths (180) that were born preterm.
Number of subjects: 39562
Study 31600823 — intervention group
Group type: COMPARATOR
Intervention: Low birthweight babies (compared to normal birthweight).
Number of subjects: 39562
Study 31600823 — intervention group
Group type: COMPARATOR
Intervention: Preterm babies (compared to term babies).
Number of subjects: 39562
Study 29914566 — intervention group
Group type: EXPERIMENTAL
Intervention: Socioemotional and material learning paradigm (SEMLA)
Number of subjects: 432
Study 29914566 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual, digitally implemented attention and math training paradigm (DIL)
Number of subjects: 432
Study 29914566 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 432
Study 27113628 — intervention group
Group type: EXPERIMENTAL
Intervention: Intradialytic resistance exercise for 8 weeks
Number of subjects: 13
Study 27113628 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 13
Study 24845171 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of oral 17β‐estradiol valerate and micronized progesterone (group 1, n=10)
Number of subjects: 30
Study 24845171 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral 17β‐estradiol valerate (group 2, n=10)
Number of subjects: 30
Study 24845171 — intervention group
Group type: COMPARATOR
Intervention: Placebo (group 3, n=10)
Number of subjects: 30
Study 22635020 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal tampons releasing chlorhexidine
Number of subjects: 20
Study 22635020 — intervention group
Group type: COMPARATOR
Intervention: Neutral tampons (placebo)
Number of subjects: 20
Study 20121659 — intervention group
Group type: EXPERIMENTAL
Intervention: Fesoterodine 4 mg
Number of subjects: 1674
Study 20121659 — intervention group
Group type: EXPERIMENTAL
Intervention: Fesoterodine 8 mg
Number of subjects: 1674
Study 20121659 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1674
Study 18928092 — intervention group
Group type: EXPERIMENTAL
Intervention: Suhuang Zhike Capsule (SZC), 3 capsules three times daily for 7 days
Number of subjects: 280
Study 18928092 — intervention group
Group type: COMPARATOR
Intervention: Zhike Ningsuo Capsule (ZNC), 3 capsules three times daily for 7 days
Number of subjects: 280
Study 16861715 — intervention group
Group type: EXPERIMENTAL
Intervention: Intubation within 2 hours of admission with cholinergic features
Number of subjects: 376
Study 16861715 — intervention group
Group type: EXPERIMENTAL
Intervention: Intubation after 24 hours while conscious and without cholinergic features
Number of subjects: 376
Study 16861715 — intervention group
Group type: EXPERIMENTAL
Intervention: Ventilation duration
Number of subjects: 376
Study 12736566 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment B (FT + TAM 20 mg/day for 2 years)
Number of subjects: 428
Study 12736566 — intervention group
Group type: COMPARATOR
Intervention: Treatment A (FT 600 mg/day for 2 years)
Number of subjects: 428
Study 11138583 — intervention group
Group type: EXPERIMENTAL
Intervention: Isometric electrical stimulation training to both legs for 60 min, five times per week for 16 weeks
Number of subjects: 6
Study 11138583 — intervention group
Group type: COMPARATOR
Intervention: Untrained (control) group
Number of subjects: 6
Study 8969280 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet P (32 g protein/d)
Number of subjects: 6
Study 8969280 — intervention group
Group type: COMPARATOR
Intervention: Diet B (50 g protein/d)
Number of subjects: 6
Study 8969280 — intervention group
Group type: COMPARATOR
Intervention: Diet M (10 mmol L-methionine/d)
Number of subjects: 6
Study 1482268 — intervention group
Group type: EXPERIMENTAL
Intervention: verapamil 240 mg SR (V)
Number of subjects: 31
Study 1482268 — intervention group
Group type: EXPERIMENTAL
Intervention: nifedipine 20 mg SR (N)
Number of subjects: 31
Study 4006378 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral pseudoracemic verapamil (160 mg)
Number of subjects: 0
Study 4006378 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral d‐verapamil (250 mg)
Number of subjects: 0
Study 4006378 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral l‐verapamil (100 mg)
Number of subjects: 0
Study 4006378 — intervention group
Group type: COMPARATOR
Intervention: Intravenous verapamil
Number of subjects: 0
Study 29208509 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraarticular catheter with elastomeric pump (ropivacaine+dexketoprofen)
Number of subjects: 0
Study 29208509 — intervention group
Group type: COMPARATOR
Intervention: Epidural catheter (ropivacaine)
Number of subjects: 0
Study 27978944 — intervention group
Group type: EXPERIMENTAL
Intervention: Upstream antithrombotic treatment
Number of subjects: 13726
Study 27978944 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients who bled before angiography
Number of subjects: 13726
Study 27978944 — intervention group
Group type: EXPERIMENTAL
Intervention: Bleeding before angiography
Number of subjects: 13726
Study 24521771 — intervention group
Group type: EXPERIMENTAL
Intervention: tacrolimus extended-release (Astagraf XL)
Number of subjects: 638
Study 24521771 — intervention group
Group type: EXPERIMENTAL
Intervention: tacrolimus (Prograf)
Number of subjects: 638
Study 24521771 — intervention group
Group type: COMPARATOR
Intervention: cyclosporine (CsA)
Number of subjects: 638
Study 24273568 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 24273568 — intervention group
Group type: EXPERIMENTAL
Intervention: Allergen
Number of subjects: 0
Study 24273568 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo and Allergen
Number of subjects: 0
Study 20693157 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifibrol (600 mg/d)
Number of subjects: 16
Study 20693157 — intervention group
Group type: COMPARATOR
Intervention: Pravastatin (40 mg/d)
Number of subjects: 16
Study 18404267 — intervention group
Group type: EXPERIMENTAL
Intervention: GRASE (Gradient and Spin-Echo) magnetic resonance imaging
Number of subjects: 35
Study 18404267 — intervention group
Group type: EXPERIMENTAL
Intervention: Turbo-spin-echo (TSE) magnetic resonance imaging
Number of subjects: 35
Study 18404267 — intervention group
Group type: COMPARATOR
Intervention: Phantom test with GRASE
Number of subjects: 35
Study 15842142 — intervention group
Group type: EXPERIMENTAL
Intervention: Ginkgo biloba extract 1 g, three times a day
Number of subjects: 45
Study 15842142 — intervention group
Group type: COMPARATOR
Intervention: Prednisone 30 mg, once a day
Number of subjects: 45
Study 12893151 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-articular drain
Number of subjects: 49
Study 12893151 — intervention group
Group type: COMPARATOR
Intervention: No intra-articular drain
Number of subjects: 49
Study 10582873 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg of azithromycin daily for 6 weeks
Number of subjects: 88
Study 10582873 — intervention group
Group type: EXPERIMENTAL
Intervention: 1,200 mg of azithromycin daily for 6 weeks
Number of subjects: 88
Study 10582873 — intervention group
Group type: EXPERIMENTAL
Intervention: Both dose groups (600 mg and 1,200 mg)
Number of subjects: 88
Study 10582873 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 88
Study 8671379 — intervention group
Group type: EXPERIMENTAL
Intervention: High vaginal deposition of seminal fluid separated from the husband's ejaculate
Number of subjects: 319
Study 8671379 — intervention group
Group type: COMPARATOR
Intervention: Normal saline solution (control group)
Number of subjects: 319
Study 8671379 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-participants with unregulated intercourse
Number of subjects: 319
Study 8671379 — intervention group
Group type: EXPERIMENTAL
Intervention: High vaginal deposition of seminal fluid
Number of subjects: 319
Study 1831017 — intervention group
Group type: EXPERIMENTAL
Intervention: 800 mg of oral ibuprofen preoperatively
Number of subjects: 30
Study 1831017 — intervention group
Group type: COMPARATOR
Intervention: 75 micrograms of intravenous fentanyl intraoperatively
Number of subjects: 30
Study 6120763 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorazepam (4 to 10 mg IV)
Number of subjects: 61
Study 6120763 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonazepam (1 mg IV)
Number of subjects: 61
Study 6120763 — intervention group
Group type: EXPERIMENTAL
Intervention: Both drugs
Number of subjects: 61
Study 30295335 — intervention group
Group type: EXPERIMENTAL
Intervention: Crizanlizumab 5 mg/kg
Number of subjects: 0
Study 30295335 — intervention group
Group type: COMPARATOR
Intervention: Crizanlizumab
Number of subjects: 0
Study 26895416 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength of Cultural Affiliation Scale (SCAS)
Number of subjects: 604
Study 27022111 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen plus OFS
Number of subjects: 1722
Study 27022111 — intervention group
Group type: COMPARATOR
Intervention: Tamoxifen alone
Number of subjects: 1722
Study 25131223 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human cytotoxic T-lymphocyte-associated antigen-4 immunoglobulin (RhCTLA4-Ig)
Number of subjects: 56
Study 25131223 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab
Number of subjects: 56
Study 25131223 — intervention group
Group type: COMPARATOR
Intervention: Methotrexate (MTX)
Number of subjects: 56
Study 25131223 — intervention group
Group type: EXPERIMENTAL
Intervention: Biologics-treated groups (RhCTLA4-Ig and infliximab combined)
Number of subjects: 56
Study 22423139 — intervention group
Group type: EXPERIMENTAL
Intervention: Trivalent inactivated influenza vaccine (TIV)
Number of subjects: 115
Study 19318275 — intervention group
Group type: EXPERIMENTAL
Intervention: PVA+Inc
Number of subjects: 54
Study 19318275 — intervention group
Group type: COMPARATOR
Intervention: PVA
Number of subjects: 54
Study 19318275 — intervention group
Group type: COMPARATOR
Intervention: PVS
Number of subjects: 54
Study 17631800 — intervention group
Group type: EXPERIMENTAL
Intervention: Yiqi Tongmai Oral Liquid (YQTM)
Number of subjects: 219
Study 17631800 — intervention group
Group type: COMPARATOR
Intervention: Shuxin Oral Liquid (SX)
Number of subjects: 219
Study 15675261 — intervention group
Group type: EXPERIMENTAL
Intervention: 4% articaine with 1:100,000 epinephrine
Number of subjects: 51
Study 15675261 — intervention group
Group type: COMPARATOR
Intervention: 2% lidocaine with 1:100,000 epinephrine
Number of subjects: 51
Study 15675261 — intervention group
Group type: EXPERIMENTAL
Intervention: Both anesthetic solutions
Number of subjects: 51
Study 12080400 — intervention group
Group type: EXPERIMENTAL
Intervention: alpha-tocopherol (50 mg/day)
Number of subjects: 26951
Study 12080400 — intervention group
Group type: EXPERIMENTAL
Intervention: beta-carotene (20 mg/day)
Number of subjects: 26951
Study 12080400 — intervention group
Group type: EXPERIMENTAL
Intervention: both alpha-tocopherol and beta-carotene
Number of subjects: 26951
Study 12080400 — intervention group
Group type: EXPERIMENTAL
Intervention: dietary vitamin C or E, alpha- or gamma-tocopherol, retinol, alpha- or beta-carotene, lycopene or lutein+zeaxanthin
Number of subjects: 26951
Study 12080400 — intervention group
Group type: EXPERIMENTAL
Intervention: serum alpha-tocopherol, beta-carotene or retinol
Number of subjects: 26951
Study 9579716 — intervention group
Group type: EXPERIMENTAL
Intervention: roxithromycin 300 mg po od
Number of subjects: 60
Study 9579716 — intervention group
Group type: COMPARATOR
Intervention: clarithromycin 500 mg po bd
Number of subjects: 60